Thrivent Financial for Lutherans
CLVS

Thrivent Financial for Lutherans’s Clovis Oncology, Inc. CLVS Stock Holding History

Thrivent Financial for Lutherans’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-62,287
Closed -$363K – 2507
2020
Q3 		$363K Sell
62,287
-421
-0.7% -$2.52K ﹤0.01% 2119
2020
Q2 		$423K Hold
62,708
– – ﹤0.01% 1977
2020
Q1 		$399K Buy
+62,708
New +$503K ﹤0.01% 1842

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Thrivent Financial for Lutherans's CLVS Position: Q4 2020 in Review

Thrivent Financial for Lutherans sold out of Clovis Oncology, Inc. (CLVS) in Q4 2020, closing a stake of 62,287 shares — an estimated $363K sold.

Thrivent Financial for Lutherans first reported a position in CLVS in Q1 2020 and held it in 3 quarters. The position peaked at $423K in Q2 2020. 159 funds tracked by Wall St. Rank hold CLVS as of Q4 2020.

  • Thrivent Financial for Lutherans reported no remaining Clovis Oncology, Inc. position as of Q4 2020 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 62,287 Clovis Oncology, Inc. shares in Q4 2020, an estimated $363K.
  • Thrivent Financial for Lutherans first reported a position in Clovis Oncology, Inc. in Q1 2020 and held it in 3 quarters.
  • Thrivent Financial for Lutherans's Clovis Oncology, Inc. position peaked at $423K in Q2 2020.
  • 159 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2020.

Based on Thrivent Financial for Lutherans's 13F filing for Q4 2020, filed 16 Feb 2021.